IRVINE, Calif.--(BUSINESS WIRE)--Oct. 5, 2017--
Masimo (NASDAQ:
MASI) announced today the U.S. release of Trace™, patient data
visualization and reporting software designed for Masimo Root®
and Radical-7® monitors.
This press release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20171005005362/en/
Masimo Trace™ Data Visualization and Reporting Tool (Photo: Business Wire)
Trace is the first data visualization and reporting software compatible
with the full capabilities of the Masimo Root Patient Monitoring and
Connectivity Platform, including Radical-7 and Radius-7®
Pulse CO-Oximeters®, Root with integrated noninvasive blood
pressure and temperature, and connected MOC-9™ modules such as SedLine®
brain function monitoring, ISA™ and ISA OR+ capnography, and
O3® regional oximetry.
“Trace adds a valuable and powerful visualization resource to clinical
toolkits,” said Joe Kiani, Founder and CEO of Masimo. “With its unique
versatility and customizability and with access to all of Masimo’s
advanced measurement technologies, Trace offers clinicians the ability
to review and focus on the patient data patterns that matter most for
each case, in the format that provides the most insight.”
Clinicians who are interested in reviewing overnight sleep studies and
who review six-minute walk patient data can benefit from Trace’s ability
to rapidly generate standard oximetry reports, as well as customized
oximetry reports that also include acoustic respiration rate (RRa®)
and end-tidal carbon dioxide (EtCO2) data. Clinicians and
researchers can download and evaluate patient data involving advanced
rainbow SET™ parameters and capnography, SedLine, and O3 measurements.
Trace can display patient data from all of these technologies on the
same time axis, facilitating clinical case review. The ability to
annotate and store data helps clinicians build easily accessible case
histories.
Trace can communicate with Masimo devices via high-speed wired or
wireless connections, with the ability to download up to 96 hours of
patient data in seconds, aiding workflow efficiencies. Trace can provide
analytics such as the determination of the minimum, maximum, and mean
values for each measurement, the percentage of time spent at defined
parameter thresholds, threshold crossing counts, and the duration of
desaturation events. Visual tools such as trend graphs, histograms, and
event annotations are also supported. Data can be tagged with notes,
labelled with identifiers, and cropped and adjusted to allow clinicians
to focus on segments and items of interest, from which a PDF report can
be generated or CSV file exported.
@MasimoInnovates |
#Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 16 of the top 20
hospitals listed in the 2017-18 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index™ (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect™ (MOC-9™) interface, enabling other companies to
augment Root with new features and measurement capabilities. Masimo is
also taking an active leadership role in mHealth with products such as
the Radius-7™ wearable patient monitor, iSpO2®
pulse oximeter for smartphones, and the MightySat™ fingertip pulse
oximeter. Additional information about Masimo and its products may be
found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.
*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.
References
1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm
Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
2.
de-Wahl Granelli A et al. Impact of pulse oximetry screening on the
detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;338.
3.
Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events
and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology.
2010; 112(2):282-287.
4. Taenzer AH et al. Postoperative
Monitoring – The Dartmouth Experience. Anesthesia Patient Safety
Foundation Newsletter. Spring-Summer 2012.
5. McGrath SP et al.
Surveillance Monitoring Management for General Care Units: Strategy,
Design, and Implementation. The Joint Commission Journal on Quality
and Patient Safety. 2016 Jul;42(7):293-302.
6. Estimate: Masimo
data on file.
7. http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo Trace™. These forward-looking statements are
based on current expectations about future events affecting us and are
subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our
actual results to differ materially and adversely from those expressed
in our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to our
belief that Masimo's unique noninvasive measurement technologies,
including Masimo Trace, contribute to positive clinical outcomes and
patient safety; risks related to our belief that Masimo noninvasive
medical breakthroughs provide cost-effective solutions and unique
advantages; as well as other factors discussed in the "Risk Factors"
section of our most recent reports filed with the Securities and
Exchange Commission ("SEC"), which may be obtained for free at the SEC's
website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171005005362/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com